FI904842A0 - Human c3b/c4b-receptor (cr1). - Google Patents

Human c3b/c4b-receptor (cr1).

Info

Publication number
FI904842A0
FI904842A0 FI904842A FI904842A FI904842A0 FI 904842 A0 FI904842 A0 FI 904842A0 FI 904842 A FI904842 A FI 904842A FI 904842 A FI904842 A FI 904842A FI 904842 A0 FI904842 A0 FI 904842A0
Authority
FI
Finland
Prior art keywords
fragments
expression
protein
secreted
proteins
Prior art date
Application number
FI904842A
Other languages
English (en)
Other versions
FI106316B (fi
Inventor
Douglas T Fearon
Lloyd B Klickstein
Winnie W Wong
Gerald R Carson
Michael F Concino
Stephen H Ip
Savvas C Makrides
Jr Henry C Marsh
Original Assignee
Univ Johns Hopkins
Brigham & Womens Hospital
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Brigham & Womens Hospital, T Cell Sciences Inc filed Critical Univ Johns Hopkins
Publication of FI904842A0 publication Critical patent/FI904842A0/fi
Application granted granted Critical
Publication of FI106316B publication Critical patent/FI106316B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Joining Of Building Structures In Genera (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI904842A 1988-04-01 1990-10-01 Ihmisen C3b/C4b-reseptori (CR1) FI106316B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17653288A 1988-04-01 1988-04-01
US17653288 1988-04-01
US8901358 1989-03-31
PCT/US1989/001358 WO1989009220A1 (en) 1988-04-01 1989-03-31 THE HUMAN C3b/C4b RECEPTOR (CR1)
US41274589A 1989-09-26 1989-09-26
US41274589 1989-09-26

Publications (2)

Publication Number Publication Date
FI904842A0 true FI904842A0 (fi) 1990-10-01
FI106316B FI106316B (fi) 2001-01-15

Family

ID=26872337

Family Applications (2)

Application Number Title Priority Date Filing Date
FI904842A FI106316B (fi) 1988-04-01 1990-10-01 Ihmisen C3b/C4b-reseptori (CR1)
FI20002515A FI115528B (fi) 1988-04-01 2000-11-16 Menetelmä rekombinanttisen, liukoisen tyypin I komplementtireseptorimolekyylin puhdistamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20002515A FI115528B (fi) 1988-04-01 2000-11-16 Menetelmä rekombinanttisen, liukoisen tyypin I komplementtireseptorimolekyylin puhdistamiseksi

Country Status (14)

Country Link
EP (1) EP0411031B1 (fi)
JP (1) JP3484189B2 (fi)
CN (2) CN1092712C (fi)
AT (1) ATE240973T1 (fi)
CA (2) CA1340866C (fi)
DE (1) DE68929466T2 (fi)
DK (1) DK175699B1 (fi)
ES (1) ES2014593A6 (fi)
FI (2) FI106316B (fi)
IL (1) IL89790A (fi)
NO (1) NO315944B1 (fi)
SG (1) SG52789A1 (fi)
WO (1) WO1989009220A1 (fi)
ZA (2) ZA892397B (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
MY107433A (en) * 1989-10-12 1995-12-30 Imutran Ltd Modiefied biological material.
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DK0574402T3 (da) * 1990-11-26 1998-05-18 Chiron Corp Ekspression af PACE i værtsceller og fremgangsmåder til anvendelse deraf
EP0560929A1 (en) * 1990-12-06 1993-09-22 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
WO1994000571A1 (en) * 1992-06-24 1994-01-06 Smithkline Beecham Plc Soluble cr1 derivatives
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
AU685433B2 (en) * 1993-02-12 1998-01-22 Regents Of The University Of Minnesota Pulmonary administration of sCR1 and other complement inhibitory proteins
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9706950D0 (en) * 1997-04-05 1997-05-21 Chernajovsky Yuti Immune modulation by polypeptides related to CR1
WO2000005413A1 (en) * 1998-07-24 2000-02-03 Uab Research Foundation Genetic polymorphism in a complement receptor
US6664052B1 (en) 1998-07-24 2003-12-16 The Uab Research Foundation Genetic polymorphism in a complement receptor
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
PL3028716T3 (pl) 2006-10-10 2021-03-08 Regenesance B.V. Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
JP5795961B2 (ja) 2008-10-21 2015-10-14 ザ ジェネラル ホスピタル コーポレイション 細胞移植
US10184110B2 (en) 2010-08-06 2019-01-22 The General Hospital Corporation System and apparatus for cell treatment
CN103237557A (zh) 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
CA2815237C (en) 2010-10-27 2018-10-09 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
ES2564290T3 (es) 2010-11-02 2016-03-21 Kypha, Inc. Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento
CN102702339B (zh) * 2011-05-24 2013-10-30 华南师范大学 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用
CN110078831A (zh) * 2011-12-01 2019-08-02 圆祥生命科技股份有限公司 补体和vegf途径的蛋白质抑制剂及其使用方法
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104293836A (zh) * 2014-06-24 2015-01-21 长沙赢润生物技术有限公司 一种免疫复合物吸附细胞的制作方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3760645A1 (en) * 2019-07-02 2021-01-06 imusyn GmbH & Co. KG Analysis for blood group antigen dacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192948A (ja) * 1984-03-14 1985-10-01 Fuji Photo Film Co Ltd 湿し水不要ネガ型感光性平版印刷版および製版方法
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)

Also Published As

Publication number Publication date
FI115528B (fi) 2005-05-31
FI106316B (fi) 2001-01-15
JPH04501502A (ja) 1992-03-19
AU647371B2 (en) 1994-03-24
DE68929466T2 (de) 2004-04-01
CA1340866C (en) 1999-12-28
NO315944B1 (no) 2003-11-17
WO1989009220A1 (en) 1989-10-05
ZA907693B (en) 1992-05-27
FI20002515A (fi) 2000-11-16
IL89790A0 (en) 1989-09-28
DK175699B1 (da) 2005-01-24
IL89790A (en) 2002-05-23
EP0411031A4 (en) 1992-02-05
CA1341443C (en) 2003-10-07
CN1092712C (zh) 2002-10-16
DE68929466D1 (de) 2003-06-26
CN1036987A (zh) 1989-11-08
EP0411031A1 (en) 1991-02-06
CN1053265A (zh) 1991-07-24
NO20000827D0 (no) 2000-02-18
DK234890A (da) 1990-11-30
EP0411031B1 (en) 2003-05-21
ZA892397B (en) 1989-11-29
NO20000827L (no) 1990-11-09
SG52789A1 (en) 1998-09-28
ATE240973T1 (de) 2003-06-15
ES2014593A6 (es) 1990-07-16
CN1053924C (zh) 2000-06-28
JP3484189B2 (ja) 2004-01-06
DK234890D0 (da) 1990-09-28
AU3539489A (en) 1989-10-16

Similar Documents

Publication Publication Date Title
ATE256181T1 (de) Menschlicher c3b/c4b-rezeptor (cr1)
DE68929466D1 (de) Menschlicher rezeptor c3b/c4b (cr1)
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
HUT77578A (hu) A 10-es számú fibroblaszt növekedési faktor (FGF-10)
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
BR9809914A (pt) Genes de moracella receptores de lactoferrina
MX9203654A (es) Purificacion, clonacion y caracterizacion del gen para la interleucina i.
JPH05503512A (ja) 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
KR970705635A (ko) 사람 케모킨 베타-9(Human chemokine beta-9)
ES2243942T3 (es) Isoforma intracelular del antagonista del receptor de la interleuquina.
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
RU2214273C2 (ru) ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ, КОДИРУЮЩИЕ ЧЕЛОВЕЧЕСКИЕ ПРОТЕИНЫ Tx И Ty, РОДСТВЕННЫЕ КОНВЕРГИРУЮЩЕМУ ИНТЕРЛЕЙКИН-1-β ФЕРМЕНТУ
PT83939B (pt) Metodo para a producao de factor angiogenico da placenta humana capaz de estimular a sintese de proteases, sintese de dna e migracao de celulas endoteliais capilares
EP0913470A3 (en) The human C3b/C4b receptor (CR1)
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
KR930701475A (ko) 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법
BR0208140A (pt) Polipeptìdeo, agente imunoterapêutico para o tratamento de psorìase, sequência de ácido nucléico isolada ou seu complemento, vetores de filamento único, e de filamento duplo, sequência de ácido nucléico isolada ou variante imunogênica da mesma, métodos para a produção de polipeptìdeos, e para o tratamento e a remissão clìnica de psorìase, e, célula hospedeira microbiana
WO1987007617A1 (en) A novel protein, neuroleukin

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: THE JOHNS HOPKINS UNIVERSITY

FG Patent granted

Owner name: AVANT IMMUNOTHERAPEUTICS, INC.

Owner name: THE JOHNS HOPKINS UNIVERSITY

Owner name: THE BRIGHAM AND WOMEN S HOSPITAL